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ABSTRACT  44 
Pulmonary inhalation chemotherapeutic drug delivery offers many advantages for lung cancer 45 
patients in comparison to conventional systemic chemotherapy. Inhalable particles are 46 
advantageous in their ability to deliver drug deep in the lung by utilizing optimally sized 47 
particles and higher local drug dose delivery. In this work, spray-dried and co-spray dried 48 
inhalable lung surfactant-mimic PEGylated lipopolymers as microparticulate/nanoparticulate dry 49 
powders containing paclitaxel were rationally designed via organic solution advanced spray 50 
drying (no water) in closed-mode from dilute concentration feed solution. 51 
Dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine 52 
poly(ethylene glycol) (DPPE-PEG) with varying PEG chain length were mixed with varying 53 
amounts of paclitaxel in methanol to produce co-spray dried microparticles and nanoparticles. 54 
Scanning electron microscopy showed the spherical particle morphology of the inhalable 55 
particles. Thermal analysis and X-ray powder diffraction confirmed the retention of the 56 
phospholipid bilayer structure in the solid-state following spray drying, the degree of solid-state 57 
molecular order, and solid-state phase transition behavior. The residual water content of the 58 
particles was very low as quantified analytically Karl Fisher titration. The amount of paclitaxel 59 
loaded into the particles was quantified which indicated high encapsulation efficiencies (43-60 
99%).  Dry powder aerosol dispersion performance was measure in vitro using the Next 61 
Generation Impactor™ (NGI™) coupled with the Handihaler® dry powder inhaler device and 62 
showed mass median aerodynamic diameters in the range of 3.4 – 7µm. These results 63 
demonstrate that this novel microparticulate/nanoparticulate chemotherapeutic PEGylated 64 
phospholipid inhalation aerosol platform has great potential in lung cancer drug delivery. 65 
 66 
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1.1 INTRODUCTION  71 
Inhalation aerosol delivery dates back to ancient times (Hickey and Mansour, 2009; Patton and 72 
Byron, 2007) and aerosol formulations have been investigated for many pulmonary diseases 73 
including lung infections, cystic fibrosis, chronic obstructive pulmonary disease (COPD), and 74 
lung cancer (Arnold et al., 2007; Cartiera et al., 2010; Meenach et al., 2012a; Watts et al., 2008; 75 
Wu et al., 2010; Yang et al., 2009). The lung is an ideal target for drug delivery owing to the 76 
potential to avoid first-pass metabolism, enable a more rapid onset of therapeutic action, high 77 
local drug concentrations within the lung, and minimization of systemic absorption of the drug 78 
allowing for decreased side effects (Carvalho et al., 2011; Gill et al., 2007; Hickey and Mansour, 79 
2008; Mansour et al., 2009; Sharma et al., 2001; Vaughn et al., 2006). Additionally, for many 80 
drugs delivery via intravenous or oral administration routes often result in high systemic drug 81 
concentrations while a relatively low amount of the drug actually reaches the lung (Carvalho et 82 
al., 2011; Vaughn et al., 2006). Specifically for lung cancer, it has been shown that drug 83 
concentrations in lung tumors are often low after systemic administration of chemotherapeutics 84 
which could be a cause of treatment failure and in some cases, the initiation of chemotherapeutic 85 
resistance (Gagnadoux et al., 2008). 86 
 In addition to the general advantages of aerosolized chemotherapy formulations, 87 
inhalable dry powder formulations offer further improvements in the treatment of lung cancer. 88 
This includes the ability to design the particle size and amount of drug loaded into the system, 89 
enhance solubility of the drug, and improve dry state storage allowing for long-term stability 90 
(Mansour et al., 2009; Sung et al., 2007). In this study, dry powder nanoparticle/microparticle 91 
formulations were designed via dilute organic solution advanced spray drying in closed-mode 92 
which has been optimized by our group for the delivery of therapeutics to treat various lung 93 
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diseases (Hayes et al., 2011; Li et al., 2011; Li and Mansour, 2011; Meenach et al., 2012b). 94 
Spray drying (SD) is an advanced high-throughput pharmaceutical manufacturing process which 95 
can design and efficiently produce respirable particles in the solid-state (Hickey and Mansour, 96 
2008; Kikuchi et al., 1991; Mansour et al., 2009; Mansour et al., 2011). One of the advantages of 97 
using SD is that it can allow for the controlled production of particles in terms of their size, 98 
morphology, and aerosol performance characteristics. Particle engineering is particular important 99 
for pulmonary delivery where many factors impact the performance of a particle system 100 
including the aerodynamic diameter (MMAD), particle size distribution, dispersibility, 101 
morphology, and thermodynamic stability (Chow et al., 2007; Hickey et al., 2007b). In 102 
particular, previous research has shown the effect that both size and surface roughness has on 103 
particle performance where particles with MMADs 1-2 µm deposit in the smaller (lower) 104 
airways and 5-10 µm deposit in the larger (upper) airways (Vehring et al., 2007) and particles 105 
with increase surface roughness may have increased dispersibility properties due to decreased 106 
interparticulate interactions between the particles (Gilani et al., 2005).  107 
While aerosol dry powder formulations utilizing polymers such as poly(lactic-co-108 
glycolic) (PLGA) (Tomoda et al., 2009) and poly(ethylene glycol)-co-poly(sebacic acid) (PEG-109 
PSA) (Tang et al., 2010) have been developed for lung cancer treatment applications, the 110 
introduction of foreign matter to the lung has the potential to induce complications. In this work, 111 
a first-line lung cancer chemotherapeutic drug, paclitaxel (PTX), was encapsulated in a 112 
PEGylated phospholipid microparticle/nanoparticle system comprised of 113 
dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine-114 
methoxy(polyethylene glycol) (DPPE-PEG). DPPC was chosen as the main excipient because it 115 
is the primary phospholipid component in lung surfactant (Mansour et al., 2011). In addition to 116 
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offering a natural excipient component to the formulated particles, the use of phospholipids as 117 
biocompatible biodegradable excipients can aid in the delivery of drugs to the lungs as they have 118 
been shown to improve particle migration to the lung periphery due to the reduction in surface 119 
tension provided by the surfactant (Ganguly et al., 2008; Mansour et al., 2001; Mansour and 120 
Zografi, 2007a, b). The use of PEGylated phospholipids, such as DPPE-PEG, can result in a 121 
formulation that could evade recognition and uptake of the immune system allowing for 122 
prolonged residence time in the lung (Ishihara et al., 1998; Labiris and Dolovich, 2003a, b; 123 
Mansour et al., 2011; Mansour et al., 2010), have mucopenetrating properties (Lai et al., 2009a; 124 
Lai et al., 2009b), and are used in marketed intravenous (IV) nanopharmaceutical products 125 
(Mansour et al., 2011; Mansour et al., 2010; Rhee and Mansour, 2011; Wu and Mansour, 2011).  126 
Also, for certain formulations, the relatively low clearance rate in the bronchioalveolar region 127 
may also allow for longer residence times (Carvalho et al., 2011). We have recently reported on 128 
the successful design and optimization of the novel DPI nanomedicine carrier platform 129 
consisting of DPPC/DPPE-PEG with varying PEG chain length and excellent aerosol dispersion 130 
performance as aerosolized dry powders (Meenach et al., 2012b). 131 
Paclitaxel was chosen for this study since it is one of the most widely used drugs to treat 132 
lung cancer and is a first-line drug in the treatment of lung cancer (Carvalho et al., 2011; Eldar-133 
Boock et al., 2011). Taxol®, the intravenous formulation of paclitaxel contains water-insoluble 134 
paclitaxel along with a mixture of Cremophor EL and dehydrated ethanol, and has been shown to 135 
cause adverse reactions such as hypersensitivity, muscle pain, and neurologic and cardiac 136 
toxicities (Marupudi et al., 2007). Paclitaxel is lipophilic, with high protein affinity, and also 137 
exhibits a volume of distribution much higher than the total water volume in the body, which 138 
causes it to have a low therapeutic index (Carvalho et al., 2011). The low solubility of paclitaxel 139 
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in water (0.7 to 30 µg/ml) (Liggins et al., 1997) can be overcome via encapsulation into a solid-140 
state particle system helping to overcome this major hurdle. 141 
The objective of this systematic study was to rationally develop and characterize an 142 
inhalable PEGylated phospholipid microparticulate/nanoparticulate dry powder aerosol platform 143 
containing paclitaxel with varying PEG chain lengths and paclitaxel content for the treatment of 144 
lung cancer. The organic solution advanced co-spray dried (co-SD) paclitaxel/PEGylated 145 
phospholipid dry powder inhalation aerosol microparticulate/nanoparticulate formulations were 146 
compared to one-component systems of spray dried paclitaxel.  The formulated particles 147 
contained a fixed amount of DPPC to DPPE-PEG with varying PEG chain lengths of 2k, 3k, and 148 
5k and with varying paclitaxel ratios (5, 25, 50, and 75 mole % of paclitaxel overall). To the 149 
authors’ knowledge, this is the first time to report on a comprehensive and systematic study on 150 
this novel anticancer lipopolymeric dry powder inhalation aerosol formulation platform 151 
engineered from organic solution advanced spray drying (i.e. no water) consisting of 152 
microparticles and nanoparticles of DPPC and DPPE-PEG with varying PEG chain lengths with 153 
various combinations of PTX for pulmonary chemotherapeutic delivery in lung cancer. 154 
 155 
2.1 MATERIALS AND METHODS 156 
2.1.1 Materials  157 
Synthetic dipalmitoylphosphatidylcholine (DPPC, Molecular Weight: 734.039 g/mol; >99% 158 
purity) and dipalmitoylphosphatidylethanolamine-methoxy(polyethylene glycol) (DPPE-PEG, 159 
Molecular Weights: 2749.391 g/mol, 3716.304 g/mol, and 5741.510 g/mol which correspond to 160 
2000, 3000 and 5000 molecular weight poly(ethylene glycol) lengths per compound; >99% 161 
purity) were obtained from Avanti Polar Lipids (Alabaster, AL, USA). Paclitaxel was obtained 162 
from LC Labs (Woburn, MA, USA; 99.5% purity; C47H51NO14·H2O). Methanol (HPLC grade, 163 
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ACS certified) and chloroform (HPLC grade, ACS certified) were obtained from Fisher 164 
Scientific (Pittsburg, PA, USA). HYDRANAL@-Coulomat AD was from Sigma-Aldrich (St. 165 
Louis, MO, USA). Ultra-high purity (UHP) dry nitrogen gas was from Scott-Gross (Lexington, 166 
KY, USA). All materials were used as received and stored at -20°C. 167 
    168 
2.1.2 Spray-Drying and Co-Spray Drying from Dilute Drug Feed Solution  169 
Advanced spray-drying of co-spray dried (co-SD) paclitaxel-loaded PEGylated phospholipid 170 
particles was performed using a B-290 Büchi Mini Spray Dryer coupled with a B-295 Inert Loop 171 
and high performance cyclone (all from Büchi Labortechnik AG, Switzerland) in closed-mode 172 
using UHP dry nitrogen as the atomizing gas. The nozzle diameter (composed of stainless steel) 173 
was 0.7 mm and the spray-drying (SD) particles were separated from the drying gas (using UHP 174 
dry nitrogen) in the high-performance cyclone and collected in a sample collector. The feed 175 
solutions were prepared by dissolving DPPC and DPPE-PEG (i.e. 95 mole % DPPC to 5 mole % 176 
DPPE-PEG) with different amounts of paclitaxel (PTX) ranging from 5 to 75 mole% paclitaxel 177 
to total DPPC/DPPE-PEG in methanol to form dilute concentration feed solutions of 0.1% w/v. 178 
Based on our previous work (Li et al., 2011; Li and Mansour, 2011; Meenach et al., 2012b), the 179 
following spray-drying conditions were used: atomization gas flow rate of 600 L/h, aspiration 180 
rate of 35 m3/h, inlet temperature of 150 °C (which represents the primary drying step), and 181 
pump rate of 30 mL/min (High P). Table I shows the various formulated particle systems and 182 
their corresponding PTX and DPPC/DPPE-PEG amounts and types and outlet temperatures 183 
(which represent the secondary drying process temperatures). For pure spray dried (SD) 184 
paclitaxel particles, the same atomization gas flow rate, aspiration rate, and inlet temperatures 185 
were used as for the PEGylated phospholipid systems. The pump rate was varied at 3 mL/min 186 
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(Low P), 15 mL/min (Med P), and 30 mL/min (High P). All SD and co-SD powders were stored 187 
in glass vials sealed with parafilm in desiccators over indicated DrieriteTM desiccant at -23°C 188 
under ambient pressure.  189 
 190 
2.1.3 Scanning Electron Microscopy (SEM) for Morphology and Shape Analysis 191 
The shape and surface morphology of particles was evaluated by SEM, using a Hitachi S-4300 192 
microscope (Tokyo, Japan). Samples were placed on double-sided adhesive carbon tabs and were 193 
adhered to aluminum stubs (TedPella, Inc., Redding, CA, USA) which were coated with a 194 
gold/palladium alloy thin film using an Emscope SC400 sputter coating system at 20 µA for 1 195 
minute under Argon gas. The electron beam with an accelerating voltage of 5 - 10 kV was used 196 
at a working distance of 13.3 – 15.3 mm. Images were captured at several magnifications using 197 
similar conditions previously reported by the authors.(Meenach et al., 2012b) 198 
 199 
2.1.4 Particle Sizing and Size Distribution 200 
The mean size, standard deviation, and size range of the particles were determined digitally using 201 
SigmaScanTM 5.0 software (Systat, San Jose, CA, USA), as previously reported by the 202 
authors.(Meenach et al., 2012b) Representative micrographs for each particle sample at 5,000x 203 
magnification were analyzed by measuring the diameter of at least 100 particles per image.   204 
 205 
2.1.5 Karl Fisher (KF) Coulometric Titration 206 
The water content of all particle powders was chemically quantified by Karl Fisher (KF) 207 
coulometric titration, using similar conditions previously reported by the authors.(Li and 208 
Mansour, 2011; Meenach et al., 2012b) The measurements were performed with a 737 KF 209 
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Coulometer coupled with 703 Ti Stand (Metrohm Ltd., Antwerp, Belgium). Approximately 5 mg 210 
of powder was dissolved in a known volume of chloroform. The sample solution was injected 211 
into the reaction cell that contained HYDRANAL® KF reagent and the water content was then 212 
calculated from the resulting reading. 213 
 214 
2.1.6 Differential Scanning Calorimetry (DSC) 215 
Thermal analysis and phase transition measurements were carried out using a TA Q200 DSC 216 
system (TA Instruments, New Castle, DE, USA) equipped with T-Zero® technology and an 217 
automated computer-controlled RSC-90 cooling accessory.  Using similar conditions previously 218 
reported by the authors,(Li and Mansour, 2011; Meenach et al., 2012b) 1 - 3 mg of powder was 219 
weighed into hermetic anodized aluminum T-Zero® DSC pans and were sealed hermetically 220 
sealed with the T-Zero® hermetic sealer. UHP dry nitrogen gas was used as the purging gas at 50 221 
mL/min. The heating range was 0 – 250 °C at a heating scan rate of 5.00 °C/min. 222 
 223 
2.1.7 Powder X-ray Diffraction (XRPD) 224 
XRPD patterns of powder samples were measured by a Rigaku Multiflex X-ray diffractometer 225 
(The Woodlands, TX, USA) with a slit-detector Cu Kα radiation source (40 kV, 44 mA, and λ = 226 
1.5406 Å). The scan range was 5 – 50° in 2θ with a scan rate of 2°/min at ambient temperature.  227 
The sample was placed on a horizontal quartz glass sample holder plate. 228 
 229 
2.1.8 Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy (ATR-FTIR) 230 
ATR-FTIR was performed using a Varian Inc. 7000e step-scan spectrometer (Agilent 231 
Technologies, Santa Clara, CA, USA). The particle powder was placed on the diamond ATR 232 
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crystal, covered with a glass cover slip, and held in place with a specialized clamp. ATR crystal 233 
and IR spectra were obtained at an 8 cm-1 spectral resolution between 700 and 4000 cm-1. The 234 
data was collected and analyzed using Varian Resolutions software. 235 
 236 
2.1.9 Hot-Stage Microscopy (HSM)  237 
HSM studies were completed using an Olympus BX51 polarized microscope (Olympus, Japan) 238 
equipped with an Instec STC200 heating unit and S302 hot stage (Boulder, CO, USA). The 239 
polarized light was filtered by a γ 530 nm U-TP530 filter lens. Powder samples were mounted on 240 
a cover glass and heated from 25 °C to 250 °C at a heating rate of 5 °C/min. The heating 241 
program was controlled by WinTemp software and images were digitally captured via a SPOT 242 
Insight digital camera (Diagnostic Instruments, Inc., Sterling Heights, MI, USA). 243 
 244 
2.1.10 Paclitaxel Loading Analysis via UV-Vis Spectroscopy 245 
UV-Vis was used to determine the amount of paclitaxel loaded into the formulated particle 246 
systems. The particles were dissolved in known quantities of methanol prior to analysis. The 247 
absorbance intensity was measured at 227 nm using a UV-1800 UV-Vis Shimadzu 248 
spectrophotometer and a calibration curve of paclitaxel in methanol was used. The paclitaxel 249 
encapsulation efficiency (EE) and loading was calculated as follows: 250 
 251 
Encapsulation Efficiency (EE)  =  		 
 
 		 
 
  100%      252 
 253 
Drug Loading =  		 
 
		 
 	
         254 
 255 
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2.1.11 In Vitro Aerosol Dispersion Performance via Next Generation ImpactorTM (NGITM)  256 
In accordance with United States Pharmacopeia (USP) Chapter <601> specifications on aerosols 257 
(2006) the in vitro aerosol dispersion properties of the dry powder particles were determined 258 
using the Next Generation ImpactorTM (NGITM) with a stainless steel induction port (i.e. USP 259 
throat) attachment (NGITM Model 170, MSP Corporation, Shoreview, MN, USA), equipped with 260 
specialized stainless steel NGITM gravimetric insert cups (MSP Corporation, Shoreview, MN, 261 
USA). The NGITM was coupled with a Copley TPK 2000 critical flow controller, which was 262 
connected to a Copley HCP5 vacuum pump (Copley Scientific, United Kingdom). The airflow 263 
rate, Q, was measured and adjusted prior to each experiment using a Copley DFM 2000 flow 264 
meter (Copley Scientific, United Kingdom).  265 
 The aerosolization studies were experimentally designed by Design Expert™ 8.0.7.1 266 
software (Stat-Ease Corp., MN, USA). Glass fiber filters (55 mm, Type A/E, Pall Life Sciences, 267 
Exton, PA, USA) were placed in the stainless steel NGITM gravimetric insert cups for NGITM 268 
stages 1 through 7 to minimize bounce or re-entrapment (Edwards et al., 1998). Three 269 
hydroxypropyl methylcellulose hard capsules (size 3, Quali-V®, Qualicaps® Inc., Whitsett, NC, 270 
USA) were each loaded with 10 mg of powder which were then loaded into a high resistance (i.e. 271 
high sheer stress) FDA-approved human DPI device, the Handihaler® (Boehringer Ingelheim & 272 
Pfizer Ltd., USA), and tightly inserted into the induction port. The NGITM was run at a controlled 273 
flow rate (Q) at 60 L/minute with a delay time of 10 seconds (NGITM Flow controller) prior to 274 
the capsules being needle-pierced open by the Handihaler® mechanism, where the particles were 275 
then drawn into the impactor for 10 seconds. This was done with a total of 3 capsules per sample 276 
for a total of 30 mg total per run. For each 30 mg run, the amount of particles deposited onto 277 
each stage was determined gravimetrically by measuring the difference in mass of the glass 278 
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filters after particle deposition. For the NGITM flow rate of 60 L/minute, the effective cutoff 279 
diameters for each impaction stage were calibrated by the manufacturer and stated as: Stage 1 280 
(8.06 µm); Stage 2 (4.46 µm); Stage 3 (2.82 µm); Stage 4 (1.66 µm); Stage 5 (0.94 µm); Stage 6 281 
(0.55 µm); and Stage 7 (0.34 µm). The fine particle dose (FPD), fine particle fraction (FPF), 282 
respirable fraction (RF), and emitted dose (ED) were calculated as follows: 283 
 284 
Fine particle dose (FPD) = mass of particles < 4.4 µm (Stages 2 through 7) 285 
 286 
Fine particle fraction (FPF) =   ! "#$
!  ! %$$ !#"" #  $&!$
 x 100% 287 
 288 
Respirable fraction (RF) = %$$ #'  !$().) µ% ,-.$ / 0#&.0 12
#!  ! %$$ # !! $.$
 x 100 % 289 
 290 
Emitted dose (ED) = ! %$$   $&!$ – ! %$$ %.   $&!$
! %$$   $&!$
  100 % 291 
 292 
The mass mean aerodynamic diameter (MMAD) and geometric standard deviation (GSD) were 293 
determined using a Mathematic program written by Dr. Warren Finlay.(Finlay, 2008) All 294 
experiments were triplicated (n = 3). 295 
 296 
2.1.12 Statistical Analysis 297 
All experiments were performed in at least triplicate. The aerosolization studies were 298 
experimentally designed by Design Expert™ 8.0.7.1 software (Stat-Ease Corp., MN, USA). 299 
MYSTAT 12 for Windows (12.01.00) was used for t-tests (paired t-test with unequal variances) 300 
14 
 
to determine any significance in observed data. A p-value of < 0.05 was considered statistically 301 
significant.  302 
 303 
3.1 RESULTS AND DISCUSSION 304 
3.1.1 SEM, Particle Sizing, and Size Distribution 305 
Formulated particle and surface morphologies were visualized and analyzed via SEM 306 
micrographs as seen in Figures 1 through 5. Their corresponding diameters are exhibited in 307 
Table I as determined via SigmaScanTM software. 5PTX:95DPPC, 5PTX:95DPPC/DPPE-308 
PEG2k, and 5PTX:95DPPC/DPPE-PEG3k particles were smooth and spherical whereas 309 
5PTX:95DPPC:DPPE-PEG5k demonstrated characteristics of sintering between the particles. 310 
25PTX:75DPPC and 25PTX:75DPPC/DPPE-PEG2k were also smooth and spherical whereas 311 
25PTX:75DPPC/DPPE-PEG3k and 25PTX:75DPPC/DPPE-PEG5k demonstrated characteristics 312 
of sintering between the particles. The 50PTX and 75PTX systems (Figures 3 and 4, 313 
respectively) demonstrated an increase in corregation as seen in Figure 5. This phenomenon was 314 
seen in our previous systems comprised of pure SD PTX (Meenach et al., 2012b). As the amount 315 
of PTX in the particle systems increased, the degree of sintering and corregation of the particles 316 
also increased. The sintering for the particles with high PEG content is likely due to the low glass 317 
transition temperature for PEG, which is around -60°C (Törmälä, 1974). The diameter of all 318 
formulated dry powder systems ranged from 0.624 to 3.416 µm in diameter and there was a 319 
slight decrease in size with increasing amounts of paclitaxel, although this was not significant. 320 
There were no changes in the diameter due to the degree of PEGylation from DPPE-PEG. 321 
Overall, the particles were within the ideal size range necessary for inhalation into the deep lung 322 
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for both adults and children (Bosquillon et al., 2001; Coates and O'Callaghan, 2006) which is 323 
necessary for effective pulmonary delivery for treating lung cancer.  324 
 325 
3.1.2 Karl Fisher (KF) Coulometric Titration 326 
The residual water content of the formulated particles in the solid-state are shown in Table I. The 327 
water content for the co-SD formulated particles ranged from 1.47 % to 6.78 % (w/w) with no 328 
trends corresponding to excipient formulation or amount of paclitaxel present in the system. The 329 
pure SD PTX particles exhibited the lowest water content ranging from 0.44 % to 2.47 % (w/w). 330 
These values were slightly higher than those reported for the raw components (Meenach et al., 331 
2012b), however, all of the values were low and well within the range previously reported by our 332 
group in other inhalable dry powder formulations. Low water content is a requirement for 333 
efficient dry powder aerosolization and effective particle delivery since water can significantly 334 
decrease the dispersion properties of dry powders during aerosolization due to the 335 
interparticulate capillary forces acting at the solid-solid interface between particles (Hickey et al., 336 
2007a). 337 
 338 
3.1.3 Differential Scanning Calorimetry (DSC) 339 
As seen in Figure 6a for the 5PTX particles, an endothermic main phase transition peak (Tc) was 340 
observed between 63°C and 65°C for all samples which corresponds to the gel-to-liquid self-341 
assembly phase transition of raw DPPC, where the hydrophobic acyl chain core melts, indicating 342 
the presence of the phospholipid bilayer structure (Mansour and Zografi, 2007a, b; Pappalardo et 343 
al., 2005). The co-SD 5PTX samples with PEG3k and PEG5k also exhibited endothermic peaks 344 
at 41.5°C and 47.2°C, respectively, which corresponds to the presence of DPPE-PEG. These two 345 
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endothermic peaks are also present in raw DPPC and DPPE-PEG as we have shown previously 346 
(Meenach et al., 2012b). The enthalpy values for the 5PTX particles ranged from 22.1 to 25.7 J/g 347 
but there was no correlation due to the excipient used. 25PTX samples (Figure 6b) also exhibited 348 
strong transition peaks between 63°C and 66°C and 25PTX:DPPC/DPPE-PEG5k particles 349 
showed peaks near 45°C and 47°C. The enthalpy values for the 25PTX particles ranged from 350 
13.1 to 20.7 J/g but there was no correlation due to the excipient used. Both 5PTX and 25PTX 351 
systems underwent a metastable phase transition around 145°C which is likely the result of 352 
reorganization of the molecules within the particles. For the 50PTX formulated particles (Figure 353 
6c) there were no measurable transition peaks with the exception of 50PTX:50DPPC/DPPE-354 
PEG5k, which exhibited small peaks at 49.2°C and 65.54°C with corresponding enthalpies of 355 
3.045 and 0.938 J/g. These correspond to the DPPC and DPPE-PEG bilayer phase transitions, 356 
respectively. In Figure 6d, the 75PTX samples indicate no measurable transition peaks in the 357 
phospholipid region (40°C to 70°C) but did exhibit a large exothermic peak around 212°C which 358 
corresponds to the degradation of the sample (also seen in panel e for raw PTX. The size of these 359 
peaks, and corresponding enthalpies, decrease with increasing PEG content at 88.4, 71.4, 59.0, 360 
and 15.9 J/g for DPPC, PEG2k, PEG3k, and PEG5k samples, respectively. Furthermore, the 361 
75PTX formulations exhibited a glass transition temperature (Tg) near 146°C, which is a second-362 
order phase transition for the amorphous glass-to-rubbery state as seen in Figure 6f. Raw PTX 363 
exhibited a small endothermic peak around 204°C which corresponds to the melting temperature 364 
(Tm) of paclitaxel, which is a first-order phase transition whereas no measurable melting peaks 365 
were seen prior to degradation for SD samples. Both the Tg and Tm values were similar to those 366 
demonstrated by the spray dried and raw paclitaxel formulations as seen in Figure 6e and 367 
compares to what has previously been shown for raw paclitaxel (Lee et al., 2001; Liggins et al., 368 
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1997). Overall, the limited presence of transition peaks from 40 to 70°C for both 50PTX and 369 
75PTX particles indicate limited multilamellar formation of the phospholipids within the particle 370 
matrix. 371 
      372 
3.1.4 X-ray Diffraction (XRPD) 373 
X-ray powder diffractograms (Figure 7) showed the a strong peak at 21° 2Θ for  all SD 5PTX 374 
and SD 25PTX formulated particles which corresponds to the presence of the solid-state 375 
phospholipid bilayer structure (Alves and Santana, 2004) indicating that the bilayer structure is 376 
preserved in the solid-state following organic solution advanced spray drying in closed-mode. 377 
These samples also exhibited strong peaks at 19 and 23° 2Θ which designate the metastable 378 
phase of PEG as seen in previous results for PEG powders (Kang et al., 2007). The intensity of 379 
the 19 and 23° 2Θ peaks increased with increasing PEG chain length for the SD 5PTX and SD 380 
25PTX systems. The intensities of the 19 and 23° 2Θ peaks for the co-SD systems are lower 381 
overall in comparison to that seen for raw DPPC or DPPE-PEG (Meenach et al., 2012b). For the 382 
SD 50PTX and SD 75PTX formulated particles no strong peaks were present, indicating that 383 
PTX is amorphous within the particle matrix, likely with limited bilayer formation within the 384 
particles. The lack of characteristic peaks likely indicates that there is no detectable phospholipid 385 
bilayer structure for these powder systems within the detection limit of XRPD. The intensities of 386 
the peak corresponding to 21°C 2Θ decreased with increasing paclitaxel content. Raw paclitaxel 387 
showed peaks throughout its diffractograms indicating its crystallinity prior to spray drying.      388 
 389 
3.1.5 Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR-FTIR) 390 
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Formulated particles and their raw counterparts underwent ATR-FTIR analysis to determine the 391 
functional groups present in the systems (Figure 8). For both the raw DPPC and raw DPPE-PEG 392 
powders, the spectra indicated the same characteristic peaks as previously reported in literature 393 
for DPPC and PEG, respectively (Lee et al., 2001; Meenach et al., 2012b). The formulated co-394 
SD PTX:DPPC/DPPE-PEG3k particles exhibited sharp peaks at 2916 cm-1 (-CH2- 395 
antisymmetrical stretching), 2870 cm-1 (-CH2- symmetrical stretching), 1724 cm-1 (C=O ester 396 
stretching), 1465 cm-1 (-CH2- deformation), 1060 cm-1 (-C-C-), and 965 cm-1 ((-N+(CH3)3 397 
antisymmetrical stretching) which all increased with increasing paclitaxel content. These peaks 398 
were present in both raw DPPC and DPPE-PEG3k but not raw or formulated paclitaxel. For the 399 
peak at 1724 cm-1, it was split for the raw PTX but not for the spray dried particles. Overall, 400 
ATR-FTIR analysis of the solid-state particles confirmed the presence of DPPC and DPPE-PEG 401 
where appropriate through the signature peaks of each component and the difference between SD 402 
paclitaxel and raw paclitaxel was confirmed by differing spectra between the two systems. 403 
  404 
3.1.6 Cross-Polarizing Light Hot-Stage Microscopy (HSM)  405 
Representative micrographs of co-SD 5PTX:95DPPC/DPPE-PEG3k and co-SD 406 
50PTX:50DPPC/DPPE-PEG3k are shown in Figure 9. The co-SD 5PTX:95DPPC/DPPE-PEG3k 407 
formulated particles showed dark agglomerates that lack birefringency between 25°C and 60°C, 408 
which indicated a non-ordered, amorphous material. A phase transition was visualized near 409 
65°C, which likely corresponds to the gel-to-liquid self-assembly bilayer main phase transition 410 
as shown in the DSC thermogram at 65°C in Figure 6a. Melting was visualized starting at 120°C 411 
with the formation of liquid droplets with decomposition occurring at 250°C. The micrographs 412 
for co-SD 50PTX:50DPPC/DPPE-PEG3k showed large agglomerates lacking birefringency 413 
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between 25°C and 80°C and a visible phase transition began starting around 90°C as shown by 414 
deformation of the particles. Melting started around 150°C and was complete by 155°C and 415 
decomposition occurred by 225°C. Pure SD paclitaxel (100PTX) showed dark agglomerates that 416 
lack birefringency between 25°C and 170°C. The particles began melting around 180°C as seen 417 
in Figure 10a. Raw paclitaxel had dark agglomerates lacking birefringency from 25°C to 180°C. 418 
Once the paclitaxel began melting at 190°C, it exhibited birefringency until decomposition 419 
around 240°C. Overall, HSM confirmed the amorphous nature of the formulated co-SD 420 
PTX:DPPC/DPPE-PEG systems as well as for SD 100PTX particles as no birefringency was 421 
observed. It also demonstrated the stability of the particles at room and physiological 422 
temperatures. 423 
 424 
3.1.7 Paclitaxel Loading 425 
Paclitaxel loading into the PEGylated phospholipid dry powder particles was determined by 426 
dissolving them in methanol and measuring the concentration of drug via UV-Vis spectroscopy. 427 
As shown in Table I, the PTX encapsulation efficiencies for 5PTX systems was the highest 428 
(ranging from 94.7% to 99.0%) and decreased with increasing PTX content. As expected, the 429 
paclitaxel loading increased with increasing PTX content where the SD 5PTX, 25PTX, 50PTX 430 
and 75PTX systems exhibited values in the range of 41.3 - 60.2 µg/mg, 191.4 - 242.6 µg/mg, 431 
316.8 - 511.0 µg/mg, and 571.2 - 679.9 µg/mg, respectively. Furthermore, the encapsulation 432 
values for the 25 – 75% PTX-loaded particles is high enough for the dose necessary for animal 433 
treatment. In particular, systems containing 100 – 500 µg/mg PTX contain enough paclitaxel to 434 
result in a dose to rats ranging from 2 – 4 mg/kg at 2 – 5 mg particles/rat, which has been 435 
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demonstrated as an effective dose range in the treatment of an orthotopic lung cancer model (Gill 436 
et al., 2011; Yang et al., 2007).  437 
 438 
3.1.8 In Vitro Aerosol Dispersion Performance via Next Generation ImpactorTM 439 
The aerosol dispersion properties of the co-SD particles and pure PTX SD particles were 440 
evaluated using the Next Generation ImpactorTM (NGITM) coupled with a Handihaler® DPI 441 
device. As seen in Table II, the MMAD values for co-SD systems (regardless of PTX loading) 442 
increased with increasing PEG chain length and decreased with increasing PTX loading. The 443 
corresponding GSD also increased with increasing PEG chain length. Furthermore, for 100PTX 444 
particles, the MMAD values were approximately the same (ranging from 3.2 µm to 3.4 µm) 445 
whereas the GSD values were 2.3 µm to 2.6 µm. In general, fine particle fractions (FPF) and 446 
respirable fractions (RF) decreased with increasing PEG content, while the emitted dose (ED) 447 
increased. There was no discernible difference for FPF, RF, and ED with respect to the PTX 448 
loading. Figure 11 shows the aerosol dispersion performance of the dry powders as the % 449 
deposition on each NGITM stage for both the co-SD and pure PTX systems. Aerosol deposition 450 
on each NGITM stage is measurable and in particular, deposition on the lower stages of stage 2 all 451 
the way to stage 7 (lowest stage) is observed.  In general, the % deposition on stage 1 increased 452 
with increasing PEG chain length. The exception to this was seen for the SD 50PTX dry powder 453 
aerosols where no difference was seen due to PEG chain length. This trend was opposite for 454 
stage 4 where the amount of powder deposited on this stage decreased with increasing PEG 455 
content for co-SD particles. For 100PTX SD dry powder aerosol, there was no difference 456 
between the amounts of powder deposited on each stage. In regards to paclitaxel loading, the 457 
amount of powder deposited on each stage decreased slightly with increasing PTX content. Since 458 
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there was significant particle deposition on Stages 5 – 7 (where the MMAD for these particular 459 
particles would be less than 1 µm), the particles on these stages should deposit in the lower 460 
airways of the lungs due to diffusion of the particles into this region via Brownian motion 461 
(Suarez and Hickey, 2000). Overall, the particles exhibit characteristics that will allow them to 462 
deposit in nearly all regions of the lung allowing for treatment throughout the entirety of the 463 
tissue. 464 
 The MMAD values for most of the particle systems were within the range necessary (1 – 465 
10 µm) for particles to deposit predominantly in the middle-to-deep lung regions and deposit by 466 
sedimentation due to gravitational settling (Carvalho et al., 2011; Edwards, 1995a, b; Hickey and 467 
Mansour, 2008; Hickey and Mansour, 2009; Suarez and Hickey, 2000). Furthermore, the ED 468 
values of co-SD particles remained approximately the same compared to systems without PTX 469 
(Meenach et al., 2012b). The RF values for the co-SD systems are lower than their corresponding 470 
drug-free systems reported by our group (45-50% compared to 60-70%) (Meenach et al., 2012b). 471 
While the RF values of the co-SD powders were lower than their respective values at a given 472 
PEG chain length for the PTX-free powders, their respective FPF values increased significantly 473 
(43-79% compared to 20-30%) (Meenach et al., 2012b).  474 
 475 
4.1 CONCLUSIONS  476 
This systematic and comprehensive study demonstrated for the first time that organic solution 477 
advanced spray drying and co-spray drying in closed-mode of a dilute concentration feed 478 
solution can be successfully employed to formulate high performing DPI liposphere aerosols 479 
consisting of co-spray dried paclitaxel (a first-line chemotherapeutic lung cancer drug) into a 480 
biocompatible and biodegradable lipopolymeric system (DPPE-PEG) with varying PEG chain 481 
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length and containing the essential lung surfactant phospholipid, DPPC. The physicochemical 482 
characterization of these particles indicates that they would be suitable to deliver PTX to the 483 
middle and deep regions of the lungs to deliver the drug in a targeted fashion. For multilamellar 484 
particles, a lower paclitaxel loading will likely be optimal along with a medium PEGylation 485 
(using DPPE-PEG3k). The incorporation of DPPE-PEG lipopolymer of varying PEG chain 486 
length can potentially offer enhanced mucus penetration by phospholipid spreading and PEG 487 
penetration, controlled drug release, and “stealth” property of evasion of phagocytosis by 488 
immune cells. 489 
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Table I. List of co-spray dried (co-SD) and single-component spray dried (SD) formulations and 673 
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encapsulation efficiency (EE) and loading. (n = 3, Ave ± SD) 675 
 676 
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LIST OF FIGURE LEGENDS  683 
Figure 1. SEM micrographs of co-spray dried (co-SD) PEGylated phospholipid particles with 684 
varying PEG chain length containing 5% paclitaxel (PTX): (a) co-SD 5PTX:95DPPC; (b) co-SD 685 
5PTX:95DPPC/DPPE-PEG2k; (c) co-SD 5PTX:95DPPC/DPPE-PEG3k; and (d) co-SD 686 
5PTX:95DPPC:DPPE-PEG5k. Magnification for all samples was 10,000x. 687 
 688 
Figure 2. SEM micrographs of co-spray dried (co-SD) PEGylated phospholipid particles with 689 
varying PEG chain length containing 25% paclitaxel (PTX): (a) co-SD 25PTX:75DPPC; (b) co-690 
SD 25PTX:75DPPC/DPPE-PEG2k; (c) co-SD 25PTX:75DPPC/DPPE-PEG3k; and (d) co-SD 691 
25PTX:75DPPC/DPPE-PEG5k. Magnification for all samples was 10,000x. 692 
 693 
Figure 3. SEM micrographs of co-spray dried (co-SD) PEGylated phospholipid particles with 694 
varying PEG chain length containing 50% paclitaxel (PTX): (a) co-SD 50PTX:50DPPC; (b) co-695 
SD 50PTX:50DPPC/DPPE-PEG2k; (c) co-SD 50PTX:50DPPC/DPPE-PEG3k; and (d) co-SD 696 
50PTX:50DPPC/DPPE-PEG5k. Magnification for all samples was 10,000x. 697 
 698 
Figure 4. SEM micrographs of co-spray dried (co-SD) PEGylated phospholipid particles with 699 
varying PEG chain length containing 75% paclitaxel (PTX): (a) co-SD 75PTX:25DPPC; (b) co-700 
SD 75PTX:25DPPC/DPPE-PEG2k; (c) co-SD 75PTX:25DPPC/DPPE-PEG3k; and (d) co-SD 701 
75PTX:25DPPC/DPPE-PEG5k. Magnification for all samples was 10,000x. 702 
 703 
Figure 5. SEM micrographs of spray-dried (SD) 100% paclitaxel particles (100PTX) following 704 
spray drying at three pump rates (Low P, Med P, and High P) for: (a) Raw paclitaxel (PTX); (b) 705 
SD 100PTX (Low P); (c) SD 100PTX (Med P); and (d) SD 100PTX (High P). Magnification for 706 
all samples was 10,000x. 707 
 708 
Figure 6. DSC thermograms of spray-dried (SD) and co-spray-dried (co-SD) particles with 709 
varying PTX content and PEG chain lengths for: (a) co-SD 5PTX:95 DPPC vs. co-SD 5PTX:95 710 
DPPC/DPPE-PEG; (b)  co-SD 25 PTX:75 DPPC vs. co-SD 25 PTX:75 DPPC/DPPE-PEG;  (c) 711 
co-SD 50PTX:50 DPPC vs. co-SD 50 PTX:50 DPPC/DPPE-PEG; (d) co-SD 75PTX:25 DPPC 712 
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vs. co-SD 75PTX:25DPPC/DPPE-PEG; (e) SD 100PTX from three pump rates vs. raw PTX; and 713 
(f) insert of co-SD 75PTX:25 DPPC vs. co-SD 75PTX:25DPPC/DPPE-PEG for Tg transition 714 
visualization. 715 
 716 
Figure 7. X-ray powder diffractograms of  spray-dried (SD) and co-spray-dried (co-SD) 717 
particles with varying PTX content and PEG chain lengths for:  (a) co-SD 5PTX:95 DPPC vs. 718 
co-SD 5PTX:95 DPPC/DPPE-PEG; (b)  co-SD 25 PTX:75 DPPC vs. co-SD 25 PTX:75 719 
DPPC/DPPE-PEG;  (c) co-SD 50PTX:50 DPPC vs. co-SD 50 PTX:50 DPPC/DPPE-PEG; (d) 720 
co-SD 75PTX:25 DPPC vs. co-SD 75PTX:25DPPC/DPPE-PEG; and (e) SD 100PTX at three 721 
pump rates vs. raw PTX. 722 
 723 
Figure 8. Representative ATR-FTIR spectra of co-spray-dried (co-SD) PTX:DPPC/DPPE-724 
PEG3k particles in comparison to raw DPPC and raw paclitaxel. 725 
 726 
Figure 9. Representative HSM micrographs of co-spray dried (co-SD) for: (a) co-SD 727 
5PTX:95DPPC/DPPE-PEG3k; and (b) co-SD 50PTX:50DPPC/DPPE-PEG3k particles (scale bar 728 
= 3 mm). 729 
 730 
Figure 10. Representative HSM micrographs of spray-dried (SD): (a) SD 100PTX (High P) 731 
particles; and (b) raw paclitaxel.  (Scale bar = 3 mm). 732 
 733 
Figure 11. Aerosol dispersion performance as % deposited on each stage of the Next Generation 734 
ImpactorTM (NGITM) for  spray-dried (SD) and co-spray-dried (co-SD) particles with varying 735 
PTX content and PEG chain lengths for: a) co-SD 5PTX:95 DPPC vs. co-SD 5PTX:95 736 
DPPC/DPPE-PEG; b) co-SD 25 PTX:75 DPPC vs. co-SD 25 PTX:75 DPPC/DPPE-PEG; c) co-737 
SD 50PTX:50 DPPC vs. co-SD 50 PTX:50 DPPC/DPPE-PEG;  d) co-SD 75PTX:25 DPPC vs. 738 
co-SD 75PTX:25DPPC/DPPE-PEG;  and e) SD 100PTX particles spray-dried at three pump 739 
rates (Low P, Med P, and High P). For Q= 60 L/minute, the effective cutoff diameters for each 740 
NGITM impaction stage are as follows: Stage 1 (8.06 µm); Stage 2 (4.46 µm); Stage 3 (2.82 µm); 741 
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Stage 4 (1.66 µm); Stage 5 (0.94 µm); Stage 6 (0.55 µm); and Stage 7 (0.34 µm). (n = 3, Ave ± 742 
SD)  743 
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Table I.  List of co-spray dried (co-SD) and single-component spray dried (SD) formulations 744 
and their corresponding outlet temperatures during spray drying, size, water content, and 745 
paclitaxel encapsulation efficiency (EE) and loading. (n = 3, Ave ± SD) 746 
System Outlet T (°C) Size (µm) 
Water (%) PTX EE 
(%) 
PTX Loading 
(µg PTX/mg 
particle) 
 
5PTX:95DPPC 50 0.946 ± 0.427 3.60 ± 0.37 99.0 ± 0.3 60.2 ± 1.5  
5PTX:95DPPC/DPPE-PEG2k 52 1.095 ± 0.458 4.30 ± 0.20 95.0 ± 0.2 48.4 ± 0.8  
5PTX:95DPPC/DPPE-PEG3k 54 0.963 ± 0.431 2.44 ± 0.78 99.6 ± 0.2 48.2 ± 0.1  
5PTX:95DPPC/DPPE-PEG5k 55 1.567 ± 0.673 2.25 ± 0.44 94.7 ± 0.2 41.3 ± 0.9  
25PTX:75DPPC 56 1.539 ± 0.661 3.73 ± 0.96 88.5 ± 0.1 191.4 ± 0.3  
25PTX:75DPPC/DPPE-PEG2k 55 3.416 ± 0.808 4.58 ± 1.31 82.3 ± 0.3 209.2 ± 0.9  
25PTX:75DPPC/DPPE-PEG3k 55 
Not 
measurable 2.21 ± 0.18 99.5 ± 0.4 242.6 ± 1.1 
 
25PTX:75DPPC/DPPE-PEG5k 54 
Not 
measurable 1.47 ± 0.18 95.0 ± 0.4 212.9 ± 0.9 
 
50PTX:50DPPC 50 0.801 ± 0.230 3.85 ± 0.68 85.0 ± 0.4 511.0 ± 2.0  
50PTX:50DPPC/DPPE-PEG2k 51 1.001 ± 0.316 6.78 ± 1.18 62.7 ± 0.4 316.8 ± 1.8  
50PTX:50DPPC/DPPE-PEG3k 50 1.215 ± 0.394 3.27 ± 0.27 73.0 ± 0.4 359.1 ± 1.8  
50PTX:50DPPC/DPPE-PEG5k 52 
Not 
measurable 5.78 ± 0.40 71.2 ± 0.4 330.8 ± 1.8 
 
75PTX:25DPPC 38 0.778 ± 0.306 3.78 ± 0.89 87.5 ± 0.4 679.9 ± 2.9  
75PTX:25DPPC/DPPE-PEG2k 38 0.781 ± 0.307 5.86 ± 0.38 84.6 ± 0.4 638.2 ± 3.1  
75PTX:25DPPC/DPPE-PEG3k 33 0.876 ± 0.337 1.60 ± 0.62 76.8 ± 0.4 571.2 ± 3.2  
75PTX:25DPPC/DPPE-PEG5k 35 0.765 ± 0.377 4.60 ± 0.21 82.4 ± 0.2 644.7 ± 1.5  
100PTX (Low P) 73 0.631 ± 0.265 2.28 ± 0.11 n/a n/a  
100PTX (Med P) 81 0.624 ± 0.247 1.41 ± 0.38 n/a n/a  
100PTX (High P) 41 0.672 ± 0.274 0.44 ± 0.39 n/a n/a  
 747 
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Table II. Next Generation ImpactorTM results for co-spray dried (co-SD) and one-component 748 
spray dried (SD) aerosol systems including mass median aerodynamic diameter (MMAD), 749 
geometric standard deviation (GSD), fine particle fraction (FPF) below 4.4 µm, respirable 750 
fraction (RF) below 4.4 µm, and emitted dose (ED). (n = 3, Ave ± SD) 751 
System MMAD (µm) 
GSD 
(µm) 
Fine 
Particle 
Fraction 
(%) 
Respirable 
Fraction 
(%) 
Emitted 
Dose (%) 
5PTX:95DPPC 3.4 2.4 77.9 ± 7.0 50.3 ± 0.5 80.0 ± 4.0 
5PTX:95DPPC/DPPE-PEG2k 4.7 2.4 60.1 ± 8.0 49.2 ± 2.6 89.8 ± 1.7 
5PTX:95DPPC/DPPE-PEG3k 4.9 2.9 64.1 ± 6.8 47.5 ± 6.7 90.8 ± 0.1 
5PTX:95DPPC/DPPE-PEG5k 7.5 3.8 43.3 ± 2.2 44.0 ± 0.5 94.5 ± 1.0 
25PTX:75DPPC 3.3     2.3 75.4 ± 4.0  52.4 ± 2.1 88.6 ± 6.1 
25PTX:75DPPC/DPPE-PEG2k 4.0 2.6 64.5 ± 2.0   51.7 ± 4.5 95.2 ± 2.5 
25PTX:75DPPC/DPPE-PEG3k 4.5 2.4 58.1 ± 8.0  49.1 ± 6.4 91.1 ± 3.4 
25PTX:75DPPC/DPPE-PEG5k 6.8 3.1 55.4 ± 1.0 48.8 ± 7.1 92.2 ± 6.1 
50PTX:50DPPC 3.1 2.5 65.8 ± 2.4 53.4 ± 1.3 90.1 ± 4.1 
50PTX:50DPPC/DPPE-PEG2k 3.8 2.4 67.5 ± 2.7 54.4 ± 6.2 91.1 ± 4.1 
50PTX:50DPPC/DPPE-PEG3k 4.2 2.8 62.7 ± 3.6 51.9 ± 2.5 94.5 ± 5.2 
50PTX:50DPPC/DPPE-PEG5k 5.3 3.1 62.8 ± 7.2 49.9 ± 4.2 97.9 ± 3.2 
75PTX:25DPPC 2.7 2.0 73.2 ± 6.3 52.5 ± 6.1 89.8 ± 3.3 
75PTX:25DPPC/DPPE-PEG2k 3.9 2.3 72.3 ± 4.7 53.1 ± 1.1 91.5 ± 3.9 
75PTX:25DPPC/DPPE-PEG3k 4.0 2.8 69.9 ± 2.9 54.5 ± 2.2 96.7 ± 7.1 
75PTX:25DPPC/DPPE-PEG5k 4.8 3.4 63.2 ± 4.4 54.1 ± 2.0 94.3 ± 5.2 
100PTX (Low) 3.2 2.3 70.6 ± 2.1 59.9 ± 0.8 90.2 ± 4.7 
100PTX (Med) 3.3 2.5 64.6 ± 1.3 66.6 ± 3.1 85.1 ± 9.0 
100PTX (High) 3.4 2.6 68.3 ± 1.1 65.7 ± 0.2 89.3 ± 3.2 
 752 
  753 
 754 
Figure 1. SEM micrographs of co755 
varying PEG chain length containing 5% paclitaxel (PTX): (a) co756 
5PTX:95DPPC/DPPE-PEG2k; (c) 757 
5PTX:95DPPC:DPPE-PEG5k. Magnification for all samples was 10,000x.758 
  759 
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 760 
Figure 2. SEM micrographs of co761 
varying PEG chain length containing 25% paclitaxel 762 
SD 25PTX:75DPPC/DPPE-PEG2k; (c) co763 
25PTX:75DPPC/DPPE-PEG5k. Magnification for all samples was 10,000x.764 
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 766 
Figure 3. SEM micrographs of co767 
varying PEG chain length containing 50% paclitaxel (PTX): (a) co768 
SD 50PTX:50DPPC/DPPE-PEG2k; (c) co769 
50PTX:50DPPC/DPPE-PEG5k. Magnification for all samples was 10,000x.770 
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 773 
Figure 4. SEM micrographs of co774 
varying PEG chain length containing 75% paclitaxel (PTX): (a) co775 
SD 75PTX:25DPPC/DPPE-PEG2k; (c) co776 
75PTX:25DPPC/DPPE-PEG5k. Magnification for all samples was 10,000x.777 
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 779 
Figure 5. SEM micrographs of spray780 
drying at three pump rates (Low P, Med P, and High P): (a) Raw paclitaxel (PTX); (b) SD 781 
100PTX (Low P); (c) SD 100PTX (Med P); and (d) SD 100PTX (High P). Magnification for all 782 
samples was 10,000x. 783 
 784 
 785 
 786 
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 787 
Figure 6. DSC thermograms of spray-dried (SD) and co-spray-dried (co-SD) particles with 788 
varying PTX content and PEG chain lengths for: (a) co-SD 5PTX:95 DPPC vs. co-SD 5PTX:95 789 
DPPC/DPPE-PEG; (b)  co-SD 25 PTX:75 DPPC vs. co-SD 25 PTX:75 DPPC/DPPE-PEG;  (c) 790 
co-SD 50PTX:50 DPPC vs. co-SD 50 PTX:50 DPPC/DPPE-PEG; (d) co-SD 75PTX:25 DPPC 791 
vs. co-SD 75PTX:25DPPC/DPPE-PEG; (e) SD 100PTX from three pump rates vs. raw PTX; and 792 
(f) insert of co-SD 75PTX:25 DPPC vs. co-SD 75PTX:25DPPC/DPPE-PEG for Tg transition 793 
visualization. 794 
 795 
 796 
 797 
 798 
Figure 7. X-ray powder diffractograms of  spray799 
particles with varying PTX content and 800 
co-SD 5PTX:95 DPPC/DPPE-PEG; (b)  co801 
DPPC/DPPE-PEG;  (c) co-SD 50PTX:50 DPPC 802 
co-SD 75PTX:25 DPPC vs. co-SD 75PTX:25DPPC/DPPE803 
pump rates vs. raw PTX. 804 
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Figure 8. Representative ATR-FTIR spectra of co807 
PEG3k particles in comparison to raw DPPC and raw paclitaxel.808 
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